PortalPublikationenRegional differences in stage distribution and rates of trea...

Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries

Standard

Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries. / Panunzio, Andrea; Tappero, Stefano; Piccinelli, Mattia; Cano Garcia, Cristina; Barletta, Francesco; Incesu, Reha-Baris; Law, Kyle W; Tian, Zhe; Tafuri, Alessandro; Saad, Fred; Shariat, Shahrokh F; Tilki, Derya; Briganti, Alberto; Chun, Felix K; DE Cobelli, Ottavio; Terrone, Carlo; Bourdeau, Isabelle; Cerruto, Maria A; Antonelli, Alessandro; Karakiewicz, Pierre I.

in: MINERVA UROL NEPHROL, Jahrgang 75, Nr. 4, 08.2023, S. 443-451.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Panunzio, A, Tappero, S, Piccinelli, M, Cano Garcia, C, Barletta, F, Incesu, R-B, Law, KW, Tian, Z, Tafuri, A, Saad, F, Shariat, SF, Tilki, D, Briganti, A, Chun, FK, DE Cobelli, O, Terrone, C, Bourdeau, I, Cerruto, MA, Antonelli, A & Karakiewicz, PI 2023, 'Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries', MINERVA UROL NEPHROL, Jg. 75, Nr. 4, S. 443-451. https://doi.org/10.23736/S2724-6051.23.05342-9

APA

Panunzio, A., Tappero, S., Piccinelli, M., Cano Garcia, C., Barletta, F., Incesu, R-B., Law, K. W., Tian, Z., Tafuri, A., Saad, F., Shariat, S. F., Tilki, D., Briganti, A., Chun, F. K., DE Cobelli, O., Terrone, C., Bourdeau, I., Cerruto, M. A., Antonelli, A., & Karakiewicz, P. I. (2023). Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries. MINERVA UROL NEPHROL, 75(4), 443-451. https://doi.org/10.23736/S2724-6051.23.05342-9

Vancouver

Panunzio A, Tappero S, Piccinelli M, Cano Garcia C, Barletta F, Incesu R-B et al. Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries. MINERVA UROL NEPHROL. 2023 Aug;75(4):443-451. https://doi.org/10.23736/S2724-6051.23.05342-9

Bibtex

@article{5c3c74bc56ff4393922f99b6ad70d3d3,
title = "Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries",
abstract = "BACKGROUND: We tested for regional differences across United States (US) in rates of adrenalectomy, systemic therapy, and adrenalectomy and systemic therapy combination for adrenocortical carcinoma (ACC) patients. We hypothesized that no differences exist, especially after accounting for baseline patient and tumor characteristics.METHODS: Within Surveillance, Epidemiology, and End Results (SEER) database (2004-2018), 1275 ACC patients were identified. Distribution of patient age, tumor size, ENSAT (European Network for the Study of Adrenal Tumors) stages, and treatments were tabulated and graphically displayed, according to nine geographical registries, corresponding to the population of specific states, cities or macro areas of the US on which the data are based on. Multinomial models predicted treatment probability for each patient according to registries.RESULTS: Patients count according to registries ranged from 62 to 509. Differences across registries existed for age (range 54-59 years; P=0.4), tumor size (8.5-11.0 cm; P=0.2), ENSAT stage (1-11% vs. 17-35% vs. 18-32% vs. 24-44%, in respectively ENSAT stage I, II, III, and IV), and treatment distribution (35-53% vs. 5-21% vs. 23-42%, in respectively adrenalectomy, systemic therapy, and adrenalectomy and systemic therapy combination; P=0.039). After adjustment for age, stage and year of diagnosis, clinically meaningful residual differences across registries remained for adrenalectomy (33-54%), systemic therapy (4-19%), and adrenalectomy and systemic therapy combination (20-38%). However, most variability originated from registries with smallest sample sizes.CONCLUSIONS: We identified important variability in ACC treatment according to SEER geographical registries, even after considering baseline patient and tumor characteristics. These findings may be indicative of differences in quality of care or expertise in ACC management.",
keywords = "Humans, United States/epidemiology, Middle Aged, Adrenocortical Carcinoma/epidemiology, Adrenal Cortex Neoplasms/epidemiology, Registries, Adrenal Gland Neoplasms",
author = "Andrea Panunzio and Stefano Tappero and Mattia Piccinelli and {Cano Garcia}, Cristina and Francesco Barletta and Reha-Baris Incesu and Law, {Kyle W} and Zhe Tian and Alessandro Tafuri and Fred Saad and Shariat, {Shahrokh F} and Derya Tilki and Alberto Briganti and Chun, {Felix K} and {DE Cobelli}, Ottavio and Carlo Terrone and Isabelle Bourdeau and Cerruto, {Maria A} and Alessandro Antonelli and Karakiewicz, {Pierre I}",
year = "2023",
month = aug,
doi = "10.23736/S2724-6051.23.05342-9",
language = "English",
volume = "75",
pages = "443--451",
journal = "MINERVA UROL NEPHROL",
issn = "2724-6051",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

RIS

TY - JOUR

T1 - Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries

AU - Panunzio, Andrea

AU - Tappero, Stefano

AU - Piccinelli, Mattia

AU - Cano Garcia, Cristina

AU - Barletta, Francesco

AU - Incesu, Reha-Baris

AU - Law, Kyle W

AU - Tian, Zhe

AU - Tafuri, Alessandro

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Tilki, Derya

AU - Briganti, Alberto

AU - Chun, Felix K

AU - DE Cobelli, Ottavio

AU - Terrone, Carlo

AU - Bourdeau, Isabelle

AU - Cerruto, Maria A

AU - Antonelli, Alessandro

AU - Karakiewicz, Pierre I

PY - 2023/8

Y1 - 2023/8

N2 - BACKGROUND: We tested for regional differences across United States (US) in rates of adrenalectomy, systemic therapy, and adrenalectomy and systemic therapy combination for adrenocortical carcinoma (ACC) patients. We hypothesized that no differences exist, especially after accounting for baseline patient and tumor characteristics.METHODS: Within Surveillance, Epidemiology, and End Results (SEER) database (2004-2018), 1275 ACC patients were identified. Distribution of patient age, tumor size, ENSAT (European Network for the Study of Adrenal Tumors) stages, and treatments were tabulated and graphically displayed, according to nine geographical registries, corresponding to the population of specific states, cities or macro areas of the US on which the data are based on. Multinomial models predicted treatment probability for each patient according to registries.RESULTS: Patients count according to registries ranged from 62 to 509. Differences across registries existed for age (range 54-59 years; P=0.4), tumor size (8.5-11.0 cm; P=0.2), ENSAT stage (1-11% vs. 17-35% vs. 18-32% vs. 24-44%, in respectively ENSAT stage I, II, III, and IV), and treatment distribution (35-53% vs. 5-21% vs. 23-42%, in respectively adrenalectomy, systemic therapy, and adrenalectomy and systemic therapy combination; P=0.039). After adjustment for age, stage and year of diagnosis, clinically meaningful residual differences across registries remained for adrenalectomy (33-54%), systemic therapy (4-19%), and adrenalectomy and systemic therapy combination (20-38%). However, most variability originated from registries with smallest sample sizes.CONCLUSIONS: We identified important variability in ACC treatment according to SEER geographical registries, even after considering baseline patient and tumor characteristics. These findings may be indicative of differences in quality of care or expertise in ACC management.

AB - BACKGROUND: We tested for regional differences across United States (US) in rates of adrenalectomy, systemic therapy, and adrenalectomy and systemic therapy combination for adrenocortical carcinoma (ACC) patients. We hypothesized that no differences exist, especially after accounting for baseline patient and tumor characteristics.METHODS: Within Surveillance, Epidemiology, and End Results (SEER) database (2004-2018), 1275 ACC patients were identified. Distribution of patient age, tumor size, ENSAT (European Network for the Study of Adrenal Tumors) stages, and treatments were tabulated and graphically displayed, according to nine geographical registries, corresponding to the population of specific states, cities or macro areas of the US on which the data are based on. Multinomial models predicted treatment probability for each patient according to registries.RESULTS: Patients count according to registries ranged from 62 to 509. Differences across registries existed for age (range 54-59 years; P=0.4), tumor size (8.5-11.0 cm; P=0.2), ENSAT stage (1-11% vs. 17-35% vs. 18-32% vs. 24-44%, in respectively ENSAT stage I, II, III, and IV), and treatment distribution (35-53% vs. 5-21% vs. 23-42%, in respectively adrenalectomy, systemic therapy, and adrenalectomy and systemic therapy combination; P=0.039). After adjustment for age, stage and year of diagnosis, clinically meaningful residual differences across registries remained for adrenalectomy (33-54%), systemic therapy (4-19%), and adrenalectomy and systemic therapy combination (20-38%). However, most variability originated from registries with smallest sample sizes.CONCLUSIONS: We identified important variability in ACC treatment according to SEER geographical registries, even after considering baseline patient and tumor characteristics. These findings may be indicative of differences in quality of care or expertise in ACC management.

KW - Humans

KW - United States/epidemiology

KW - Middle Aged

KW - Adrenocortical Carcinoma/epidemiology

KW - Adrenal Cortex Neoplasms/epidemiology

KW - Registries

KW - Adrenal Gland Neoplasms

U2 - 10.23736/S2724-6051.23.05342-9

DO - 10.23736/S2724-6051.23.05342-9

M3 - SCORING: Journal article

C2 - 37530661

VL - 75

SP - 443

EP - 451

JO - MINERVA UROL NEPHROL

JF - MINERVA UROL NEPHROL

SN - 2724-6051

IS - 4

ER -